Corporate | 7 December 2011 09:44
|
WILEX AG / Key word(s): Research Update
PRESS RELEASE WILEX Inc. lists Oncogene Science (R) CA IX IHC Kit as an In-Vitro-Diagnostic with the FDA Cambridge, MA, USA, and Munich, Germany, 7 December 2011. WILEX Inc., a wholly owned US subsidiary of WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange), today announced the listing of the CA IX IHC kit as a Class I 510(k)-exempt medical device with the FDA. This immunohistochemistry (IHC) kit is used to identify the antigen Carbonic Anhydrase IX (CA IX) in tissues or cytologic specimens. In addition to the Oncogene Science (R) CA IX ELISA, a research use only enzyme-linked immunoassay used for the quantitative detection of the circulating form of the CA IX protein in human serum and plasma, the IHC kit complements WILEX Inc.'s offer in the field of CA IX. WILEX Inc. focuses on the manufacturing, marketing and sales of biomarker assays and on developing companion diagnostics for targeted oncology therapies. The protein CA IX is overexpressed in many types of cancer and its expression is strongly induced by hypoxia. In a variety of human cancers, tumor hypoxia is associated with an increased incidence of metastases. CA IX measurement has been reported as a potential biomarker for clear cell renal cell carcinoma. The CA IX IHC kit is an in-vitro diagnostic device (IVD) consisting of a monoclonal antibody specific for CA IX along with HRP-labeled streptavidin-biotin immunohistochemical staining technology to detect presence of CA IX in formalin-fixed, paraffin embedded tissue sections. Positive and negative controls included assure accurate detection of CA IX in tissues. The CA IX IHC kit aids in the classification of normal and abnormal cells or tissues and serves as an adjunctive test to support conventional histopathology diagnosis.
About WILEX Inc.
About
WILEX AG
Contact Press
Contact Customer Service
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as 'estimates', 'believes', 'expects', 'may', 'will' 'should' 'future', 'potential' or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. End of Corporate News 07.12.2011 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | WILEX AG | |
| Grillparzerstr. 10 | ||
| 81675 München | ||
| Germany | ||
| Phone: | +49 (0)89 41 31 38 – 0 | |
| Fax: | +49 (0)89 41 31 38 – 99 | |
| E-mail: | info@wilex.com | |
| Internet: | www.wilex.com | |
| ISIN: | DE0006614720 | |
| WKN: | 661472 | |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart | |
| End of News | DGAP News-Service |
|
|
| 148895 07.12.2011 |